slow process, page-2

Great announcement today!!!

Doubles capacity from canadian facility -

Stirling Products (ASX:STI) advises that Stirling Products North America Incorporated (STI-NA)
has completed the first phase of the manufacturing scale-up at its Charlottetown facility. The
increase in production will satisfy future demands for its newly acquired product ProVale™,
manufactured at the facility.
CEO and Managing Director of Stirling Products, Dr Calvin London indicated that “shortly after
the acquisition of Progressive BioActives Inc. (now STI-NA), the Board approved the allocation
of funds to double the capacity at the facility.” (see ASX announcement 27 August 2007). “The
scale-up in equipment and associated doubling allows us to manufacture up to 2.5 metric tonnes
of pure ProVale™ per annum, which combined with the existing toll manufacturing capability
gives us a potential output of 5 metric tonnes per annum.”
STI-NA has recently received a grant from the NRC-IRAP under their “Network Members
Agreement”, which is administered locally by PEI Business Development Inc. The grant covers
funding to assess the feasibility and most beneficial scenario for the second and third phases of
the scale-up anticipated in 2008.
“We now have sufficient capacity and flexibility to meet the projected increase in sales
throughout 2008. Further increases in production capacity in 2008 will be introduced to meet the
expansion in ProVale™ requirements as a result of new distribution agreements such as the one
announced last month in the United States,” said Mr Shane Patelakis, President of STI-NA.
Stirling indicated to shareholders at its recent AGM, that it had established a sales revenue
target for ProVale™ and R-salbutamol (primarily from South Africa) of US$1 million by the end of
2008.
ENDS.